PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates

ACS Chemical Neuroscience
Steven H LiangNeil Vasdev

Abstract

Fluorine-18 labeled 2-fluoro-8-hydroxyquinoline ([(18)F]CABS13) is a promising positron emission tomography (PET) radiopharmaceutical based on a metal chelator developed to probe the "metal hypothesis of Alzheimer's disease". Herein, a practical radiosynthesis of [(18)F]CABS13 was achieved by radiofluorination followed by deprotection of an O-benzyloxymethyl group. Automated production and formulation of [(18)F]CABS13 resulted in 19 ± 5% uncorrected radiochemical yield, relative to starting [(18)F]fluoride, with ≥95% chemical and radiochemical purities, and high specific activity (>2.5 Ci/μmol) within 80 min. Temporal PET neuroimaging studies were carried out in female transgenic B6C3-Tg(APPswe,PSEN 1dE9)85Dbo/J (APP/PS1) and age-matched wild-type (WT) B6C3F1/J control mice at 3, 7, and 10 months of age. [(18)F]CABS13 showed an overall higher uptake and retention of radioactivity in the central nervous system of APP/PS1 mice versus WT mice with increasing age. However, PET/magnetic resonance imaging in normal nonhuman primates revealed that the tracer had low uptake in the brain and rapid formation of a hydrophilic radiometabolite. Identification of more metabolically stable (18)F-hydroxyquinolines that can be readily accessed ...Continue Reading

References

Jul 17, 1998·Journal of the Neurological Sciences·M A LovellW R Markesbery
May 14, 2005·Nature Reviews. Neuroscience·Christopher J FredericksonAshley I Bush
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ashley I Bush, Rudolph E Tanzi
Oct 28, 2008·Journal of Alzheimer's Disease : JAD·Ashley I Bush
Feb 19, 2010·Journal of Alzheimer's Disease : JAD·Noel G FauxAshley I Bush
Jan 5, 2011·CNS Neuroscience & Therapeutics·Silvio R Bareggi, Umberto Cornelli
Jul 4, 2012·Accounts of Chemical Research·Peter J Crouch, Kevin J Barnham
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Mar 20, 2013·ACS Chemical Biology·Masha G SavelieffMi Hee Lim
May 8, 2013·Journal of Alzheimer's Disease : JAD·Vladimir KepeJorge R Barrio
Aug 21, 2013·Chemical Communications : Chem Comm·Steven H LiangNeil Vasdev
Sep 28, 2013·Journal of the American Chemical Society·James L HickeyPaul S Donnelly
Dec 12, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Jason P HollandNeil Vasdev
Mar 29, 2014·Chemical Society Reviews·Lin ZhuHank F Kung
Jul 10, 2014·Nature Communications·Benjamin H RotsteinSteven H Liang
Dec 3, 2014·Biological Psychiatry·Jonathan McConathy, Yvette I Sheline
Feb 24, 2015·ACS Medicinal Chemistry Letters·Brian P CaryPeter J H Scott

❮ Previous
Next ❯

Citations

Jan 12, 2016·Chemical Reviews·Sean PreshlockVéronique Gouverneur
Feb 20, 2019·Chemical Communications : Chem Comm·So Jeong LeePeter J H Scott

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.